TriNetX study links tirzepatide to fewer diabetic foot complications than sulfonylureas

The wire

1. 01In a retrospective TriNetX cohort of adults with type 2 diabetes starting therapy between January 2022 and July 2025, tirzepatide was associated with lower risk of a composite foot-complication outcome versus sulfonylureas (HR 0.80), DPP-4 inhibitors (HR 0.83) and SGLT2 inhibitors (HR 0.88).
2. 02The composite covered ulcers, infections, critical limb ischemia, revascularization and amputation, outcomes clinicians weigh when selecting agents for patients at risk of ulceration.
3. 03Matched cohorts ranged from roughly 97,000 to 146,000 patients per arm, but the design is observational and residual confounding and coding limitations remain.

From the source

Tirzepatide versus other anti-diabetic agents for the prevention of diabetic foot complications in patients with type 2 diabetes

Frontiers in pharmacology · 2026 · Kuo CY, Wu JY, Tsai YW et al.